(EWL) MSCI Switzerland - Overview
Etf: Large-Cap Stocks, Mid-Cap Stocks, Switzerland, Equity
Dividends
| Dividend Yield | 1.90% |
| Yield on Cost 5y | 2.54% |
| Yield CAGR 5y | 2.83% |
| Payout Consistency | 87.2% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 13.9% |
| Relative Tail Risk | -0.16% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.39 |
| Alpha | 18.82 |
| Character TTM | |
|---|---|
| Beta | 0.443 |
| Beta Downside | 0.341 |
| Drawdowns 3y | |
|---|---|
| Max DD | 13.47% |
| CAGR/Max DD | 1.11 |
Description: EWL MSCI Switzerland January 17, 2026
The iShares MSCI Switzerland ETF (NYSE ARCA:EWL) commits at least 80% of its assets to securities that are either components of its benchmark index or have substantially identical economic characteristics. The underlying index is a free-float-adjusted, market-capitalization-weighted basket that tracks large- and mid-cap Swiss equities, and the fund is classified as non-diversified under U.S. regulations.
Key data points as of Q4 2025: the fund’s expense ratio is 0.20% and it holds roughly $4.2 billion in assets under management. Its top holdings are Nestlé (SW 5.5 %), Roche (SW 4.8 %), and Novartis (SW 4.5 %), which together account for about 15% of the portfolio. Sector exposure is heavily weighted toward healthcare (≈ 45%), consumer staples (≈ 20%), and financials (≈ 15%). The ETF’s performance is closely tied to Swiss macro-drivers such as the strength of the CHF, export demand for precision engineering, and global pharmaceutical pricing trends.
If you want a more granular, data-driven view of EWL’s risk-adjusted returns and factor exposures, a quick look at ValueRay can help you spot any hidden upside or downside.
What is the price of EWL shares?
Over the past week, the price has changed by +2.52%, over one month by +4.19%, over three months by +14.25% and over the past year by +28.64%.
Is EWL a buy, sell or hold?
What are the forecasts/targets for the EWL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 72.8 | 15.4% |
EWL Fundamental Data Overview February 02, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.64b USD (1.64b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.64b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.64b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.55% (E(1.64b)/V(1.64b) * Re(7.55%) + (debt-free company))
Discount Rate = 7.55% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)